JCO3 Rec'd PCT/PTO 03 OCT 2009

Substitute for Form U.S. DEPAR	TMENT OF COMMERCE	PATENT AND TRADEMARK OF	FICE	ATTORNEY'S DOCKET NUMBER							
TRANSMITTAL	012679-113										
DESIGNATED/E	U.S. APPLICATION-NO. (IF anown, see 37 CFR 1.5)										
		ER 35 U.S.C. 371		BU Dnassigned L							
INTERNATIONAL APPLICATIO	•	TERNATIONAL FILING DA		PRIORITY DATE CLAIMED							
PCT/KR2004/000	//4	2 April 2004 (02.0	4.2004)	3 April 2003 (03.04.2003)							
USE OF A PEPTIDE THA	AT INTERACTS	S WITH ALPHA V BE	TA 3 INTEG	RIN OF ENDOTHELIAL CELL							
APPLICANT(S) FOR DO/EO/US Ju-Ock NAM, Jung-Eun k PARK, Jae-Yong PARK a	KIM, Ha-Won J		E, Byung-Hed	on LEE, Je-Yong CHOI, Ran-Woon							
Applicant herewith submits to the	ne United States D	esignated/Elected Office (DO/EO/US) the	following items and other information:							
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information: 1. This is a FIRST submission to items concerning a filing under 35 U.S.C. 371.											
1 =		•		r 35 U.S.C. 371							
i	This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371. This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5),										
(6), (9) and (22) indica	ted below.			• •							
ł		on of 19 months from the p		cie 31).							
5. 🗷 A copy of the Internation											
! <u>_</u>		if not communicated by the	e International E	Bureau).							
b. L has been com	municated by the I	nternational Bureau.									
C. L is not required	, as the application	n was filed in the United St	ates Receiving (Office (RO/US).							
6. An English language tr	anslation of the Inf	ternational Application as	filed (35 U.S.C. 3	371(c)(2))							
a. is attached he	reto.										
b. has been prev	iously submitted u	nder 35 U.S.C. 154(d)(4).		·							
7. X Amendments to the cla	aims of the Internat	tional Application under Po	CT Article 19 (35	5 U.S.C. 371(c)(3))							
a. are attached h	ereto (required on	ly if not communicated by	the International	Bureau).							
b. have been cor	nmunicated by the	International Bureau.									
c. have not been	made; however, t	he time limit for making su	ch amendments	has NOT expired.							
d. 🕱 have not been	d. 🕱 have not been made and will not be made.										
8. An English language to	8. An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).										
9. X An oath or declaration	of the inventor(s)	(35 U.S.C. 371(c)(4)).									
10. An English language to											
Items 11 to 21 below cond	cern document(s)	or information included	:								
11. An Information Disclos	ure Statement und	ler 37 CFR 1.97 and 1.98.									
l <u> </u>	An Information Disclosure Statement under 37 CFR 1.97 and 1.98. X An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.										
<u> </u>		A separate cover sheet in	compliance with	137 CFR 3.26 and 3.31 is included.							
13. X A FIRST preliminary a											
14. A SECOND or SUBSE	QUENT prelimina	ry amendment.									
15. A substitute specificati	on.										
16. A change of power of a	attorney and/or add	dress letter.		•							
17. X A computer-readable f	orm of the sequen	ce listing in accordance wi	th PCT Rule 13t	er.2 and 37 C.F.R. 1.821 - 1.825.							
l <u> </u>	A second copy of the published international application under 35 U.S.C. 154(d)(4).										
19. A second copy of the E	_										
<u> </u>											
Other items or information: _1) Application Data Sheet; 2) General Authorization for Petitions for Extensions of Time and Payment of Fees; 3) Paper copy of Sequence Listing (attached to Preliminary Amendment); 4) Declaration Pursuant to 37 CFR Sections 1.821-1.825; 5) Forms PCT/ISA/202 (PCT Request), PCT/ISA/210 (Int'l Search Report), PCT/ISA/237, PCT/IB/301,											
Sections 1.821-1.825; PCT/IB/304, PCT/IB/3	<u>5) Forms PCT/ISA 08, PCT/IB/311, P</u>	vzuz (PCT Request), PCT CT/IB/332, PCT/IPEA/401	/ISA/210 (Int'l So PCT/IPEA/402	earch Report), PCT/ISA/237, PCT/IB/301, PCT/IPEA/416 and PCT/IPEA/409.							
		· · · · · · · · · · · · · · · · · · ·									

A -

JC20 Rec'd PCT/PTO 0 3 OCT 2005

.U. AI	Unassigned	יייייייייייייייייייייייייייייייייייייי	PCT/KR2004/00077	4	012679-1	
. X	Applicant(s) requests th information: _REGEN B	pplicant(s) requests that the published application include the following assignment formation: _REGEN BIOTECH. INC Seoul. Republic of Korea.				
					-	
					-	
		 			- -	
<u> </u>			 		-	
. X —	The following fees are su	ubmitted:				
Bas	sic Filing Fee (1631)				\$ 300.00	
	charge of \$130.00 (1617) nths from the earliest clair	ned priority date (37 CI	FR 1.492(e)).	20 🔲 30		
	CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE	\$	
	al Claims	12 -20		× \$50.00 (1615)		
_	ependent Claims	6 -3	= 3	* \$200.00 (1614 + \$360.00 (1616	·	
	LTIPLE DEPENDENT CL					
	mination Fee	\$ 200.00				
	rch Fee	\$ 500.00				
App	o. Size Fee (add \$250.00 f	or each add'i 50 sheets		E CALCULATIONS	0.4.000.55	
×	Applicant claims small e are reduced by 1/2.	\$ 1,600.00	<u>.</u>			
_	are reduced by 172.	. = \$800.00				
Pro	cessing fee of \$130.00 (1	•				
				AL NATIONAL FEE	= \$800.00	
	for recording the enclose ompanied by an appropria	+ \$ 40.00				
		\$ 840.00				
	_		to cover the above fees		Amount to be refunded :	
a.	A check in the amou	charged :				
b.	Please charge my De duplicate copy of this	to cover the above fees. A				
C.			charge any additional fees licate copy of this sheet is		uired, or credit any ov	erpayment to
d.	➤ Charge \$840.0	0 to credit card. I	Form PTO-2038 is attache	ed.		
	TE: Where an appropria b)) must be filed and gra				etition to revive (37	CFR 1.137(a)
					4	
SE	ND ALL CORRESPONDE	NCE TO:		Sje	san H.	J.
	rns, Doane, Swecke O. Box 1404	r & Mathis, L.L.P.		SIGNATURE	1	
	exandria, Virginia 223	313-1404	Susan M. Dadio			
	93) 836-6620					
				40,373	Octol	per 3, 2005
		N NO.	DATE			

Patent Attorney Docket No. 012679-113

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

Ju-Ock Nam et al.

Group Art Unit: Unassigned

Application No.: Unassigned

Examiner: Unassigned

Filing Date:

October 3, 2005

Confirmation No.: Unassigned

Title: USE OF A PEPTIDE THAT INTERACTS WITH ALPHA V BETA 3 INTEGRIN OF ENDOTHELIAL CELL

GENERAL AUTHORIZATION FOR PETITIONS FOR EXTENSIONS OF TIME AND PAYMENT OF FEES

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

In accordance with 37 C.F.R. §1.136(a)(3), the U.S. Patent and Trademark Office is hereby provided with a general authorization to treat any concurrent or future reply requiring a petition for an extension of time for its timely submission as containing a request therefor for the appropriate length of time.

The Commissioner is hereby authorized to charge any appropriate fees under 37 C.F.R. § 1.17 that may be required by this paper, and to credit any overpayment, to Deposit Account No. 02-4800. This paper is submitted in duplicate.

Respectfully submitted,

BUCHANAN INGERSOLL PC

P.O. Box 1404 Alexandria, Virginia 22313-1404 (703) 836-6620

Date: October 3, 2005

Registration No. 40,373